ABSTRACT
A neurologic compromise associated with vertebral fractures is generally due to a malignancy causes. Therefore, an osteoporotic vertebral fracture can sometimes cause neurologic complications. Report a case of neurologic compromise associated with osteoporotic vertebral fractures. A-62-year-old man suffered from rheumatoid arthritis since 1985, presented a cervical pain associated with quadriparesia secondary to a C5 osteoporotic vertebral fractures. Osteonecrosis may be the cause of neurologic compromise associated with osteoporotic vertebral fractures
Subject(s)
Humans , Male , Osteoporosis , Spinal Fractures , Arthritis, Rheumatoid , Cervical Vertebrae , Quadriplegia , Neck PainABSTRACT
Background: Sarcoidosis is an ubiquity disease, which can infiltrate all tissues. The cutaneous and ophthalmologic thoracic localizations are most frequent. The nasosinusienne localisation is rare
Aim: The authors report their observations of 4 patients: 2 men and 2 women with a mean age 47,5 years [42-56]. These cases was diagnosed and treated between January 1998 and December 2003 in the ENT service of the Habib Thameur hospital
Cases: The diagnosis was related to a nasal or a sinuses biopsy. The assessment of extention was negative in 3 cases. The corticoid treatment in local pulverization was sufficient in 2 cases. The corticoid treatment by systematic way was obtained in all the cases. The naso sinusienne localization is rare, it is exceptionally isolated. The clinical and radiological symptoms are not specifics. Principal element of the symptoms are not specifics. Principal element of the diagnosis is the directed biopsy, easy in this localization
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Paranasal Sinus Diseases , Nose Diseases , Adrenal Cortex Hormones/therapeutic useABSTRACT
The aim of this study was to assess the effect and safety of leflunomide [LEF] in refractory RA and to review the literature on this subject. A one year prospective study was conducted on a group of patients [n: 15]. Mean duration of the disease was 6,46 years. Rheumatoid factor was present in 12 cases. Leflunomide was administered at a dos of 20mg/day following a loading dose of 100mg/day for three days. The efficacy of LEF was evaluated on clinical and biological parameters of RA evolutivity at one, 3,6,9 and 12 months. Our mean follow up period was about 8 months [2 to 12 months]. Good prognostic indicators of disease progression were observed with LEF at one month and later in eleven cases with a good safety. Non serious adverse events were observed with LEF. Our results confirm that LEF may present another therapeutic choice that is efficacious for the long term treatment of refractory RA. Nonetheless, these results must be evaluated on a larger series
Subject(s)
Humans , Male , Female , Isoxazoles/analogs & derivatives , Adjuvants, ImmunologicABSTRACT
Current slow-acting anti-rheumatic drugs available at now for rheumatoid arthritis fail in majority of cases and have an inconstant chondro-protective effect. Improvements in our knowledge of its pathogenesis and advances in molecular biology have made possible to develop selective immunotherapy approaches. Tumor necrosis factor alfa [TNF alfa] is an important inflammatory mediator that play a crucial role in rheumatoid arthritis. This studies summarizes clinical essays that evaluate beneficial effects and tolerance of anti TNF alfa antibodies. This study showed the clinical, biological and radiological efficacy of these therapeutic agents. But some doubts persist concerning their long term side effects particularly infections, neoplasm or auto immune ones. High price of this treatment should evaluate report cost benefice to appreciate the better utilisation of these drugs